Perbedaan Gejala Psikopatologi pada Pasien HIV/AIDS yang Mendapat Terapi Berbasis Efavirenz dan Dolutegravir
DOI:
https://doi.org/10.32807/bnj.v7i2.1894Keywords:
HIV/AIDS; Efavirenz; Dolutegravir; psychopathologyAbstract
HIV/AIDS memiliki beban psikososial tinggi, termasuk stres, cemas, dan depresi. Efavirenz dilaporkan lebih sering menimbulkan efek samping neuropsikiatri dibandingkan Dolutegravir. Penelitian ini bertujuan membandingkan gejala psikopatologi pada pasien HIV/AIDS dengan terapi berbasis Efavirenz dan Dolutegravir di RSUD Dr. Moewardi Surakarta. Penelitian observasional analitik dengan desain potong lintang pada pasien HIV/AIDS di Poli VCT Januari 2022. Instrumen yang digunakan adalah DASS-21. Analisis meliputi regresi logistik, uji Shapiro-Wilk, dan t-test independent. Dari 42 pasien, 24 menggunakan Efavirenz dan 18 Dolutegravir. Regimen berhubungan signifikan dengan psikopatologi (OR = 8,330; CI 95% = 1,023–67,824; p = 0,048). Uji t-test menunjukkan perbedaan signifikan pada skor stres, cemas, dan depresi, dengan nilai rata-rata lebih tinggi pada kelompok Efavirenz (p < 0,001). Hasil analisis menunjukan Efavirenz lebih berisiko menimbulkan gejala psikopatologi dibandingkan Dolutegravir. Temuan ini mendukung penggunaan Dolutegravir sebagai pilihan yang lebih aman untuk kualitas hidup pasien. Deteksi dini dan edukasi kepatuhan terapi sangat diperlukan.
References
American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). https://doi-org.ezproxy.frederick.edu/10.1176/appi.books.978089 0425596
Arif, A, Ariyanto, Y, Ramani, A (2015). Pemetaan Faktor Risiko Kejadian HIV dan AIDS di Kabupaten Jember Tahun 2015: HIV and AIDS Risk Factors Mapping in Kabupaten Jember on 2015. Jember: Bagian Epidemiologi dan Biostatistika Kependudukan Fakultas Kesehatan Masyarakat Universitas Jember.
Blanco, J. L., Whitlock, G., Milinkovic, A., Moyle, G., Martínez, E., Villarroya, F., ... & Mallolas, J. (2019). Psychiatric and neurological adverse events with dolutegravir-based antiretroviral therapy: A Systematic Review and Meta-Analysis. Clinical Infectious Diseases, 69(10), 1780-1789.
Cabrera Figueroa S, Iglesias Gómez A, Sánchez Martín A, de la Paz Valverde Merino M, Domínguez-Gil Hurlé A, and Cordero Sánchez M (2010) Long-term efficacy and safety of efavirenz dose reduction to 200 mg once daily in a Caucasian patient with HIV. Clin Drug Investig 30:405–411.
Cervo A, Adorni F, Galli L, et al. Dolutegravir-Based Antiretroviral Therapy: An Update on Safety and Efficacy in HIV-1-Infected Adults. Ther Clin Risk Manag. 2017;13:2047- 2065. doi:10.2147/tcrm.s133301
Cervo, A., Riva, N., Galli, L., Guffanti, F., Bozzani, F., Veglia, F., ... & Castagna, A. (2017). Central nervous system adverse events of efavirenz in HIV-positive individuals: a systematic review. AIDS reviews, 19(2), 77-87.
Corr, M. 2012. HIV and Liaison Psychiatry dalam: Seminars in Liaison Psychiatry, Guthrie E., Rao S., Temple M ed. Royal College of Psychiatrists: London.
Dalwadi DA, Kim S, Amdani SM, Chen Z, Huang RQ, and Schetz JA (2016) Molecular mechanisms of serotonergic action of the HIV-1 antiretroviral efavirenz. Pharmacol Res 110:10–24
Dinas Kesehatan Provinsi Jawa Tengah (2015). Profil Kesehatan Provinsi Jawa Tengah Tahun 2015. Semarang: Dinas Kesehatan Provinsi Jawa Tengah.
Djoerban Z, Djauzi S. (2009). HIV/AIDS di Indonesia. Buku Ajar Ilmu Penyakit Dalam. Edisi Kelima. Jilid III. Jakarta: Internal Publishing.
Duko B, Toma A, Asnake S, Abraham Y. Depression, anxiety and their correlates among patients with HIV in South Ethiopia: an institutionbased cross sectional study. Front Psychiatry. 2019;10:17.
Fernández-Bargiela N, Rotea-Salvo S, Margusino-Framiñán L, Balboa-Barreiro V, Martín- Herranz I, Castro-Iglesias Á, et al. Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study. Eur J Hosp Pharm. 2022;29(4):207–211.
Foster R, Olajide D, and Everall IP (2003) Antiretroviral therapy-induced psychosis: case report and brief review of the literature. HIV Med 4:139–144
Fumaz CR, Munoz-Moreno JA, Molto J, Negredo E, Ferrer MJ, Sirera G, Perez-Alvarez N, Gomez G, Burger D, and Clotet B (2005) Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence. J Acquir Immune Defic Syndr 38:560–565
Gervasoni, C., Meraviglia, P., Landonio, S., Santambrogio, S., & Rizzardini, G. (2016). Dolutegravir and central nervous system toxicity: lights and shadows. AIDS reviews, 18(4), 213-224.
Gounden V, van Niekerk C, Snyman T, and George JA (2010) Presence of the CYP2B6 516G> T polymorphism, increased plasma Efavirenz concentrations and early neuropsychiatric side effects in South African HIV-infected patients. AIDS Res Ther 7:32
Gutiérrez F, Navarro A, Padilla S, Antón R, Masiá M, Borrás J, and Martín-Hidalgo A (2005) Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41:1648–1653.
Gutierrez M, Mateo MG, Vidal F, et al. Drug safety profile of integrase strand transfer inhibitors. Expert Opin Drug Saf. 2014;13:431–445.
Hasse B, Günthard HF, Bleiber G, and Krause M (2005) Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 40:e22–e23
Kanters S, Vitoria M, Zoratti M, Doherty M, Penazzato M, Rangaraj A, et al. Comparative efficacy, tolerability and safety of dolutegravir and efavirenz 400 mg among antiretroviral therapies for first-line HIV treatment: a systematic literature review and network meta- analysis. EClinicalMedicine 2020; 28:100573.
Kaplan HI, Sadock BJ. 2021. Neuropsychiatric Aspect of HIV Infection and AIDS, Sypnosis of Psychiatry, 12th ed. William & Wilkins, Baltimore USA. 2021 P 371 – 79
Kementrian Kesehatan Republik Indonesia (2015). Estimasi dan Proyeksi HIV AIDS di Indonesia Tahun 2011-2016.
Komisi Penanggulangan AIDS kota Surakarta (2017). Kasus HIV dan AIDS di Surakarta Sejak Oktober 2005 s/d Desember 2016. Surakarta: Komisi Penanggulangan AIDS.
Komisi Penanggulangan AIDS Provinsi Jawa Tengah (2016). Data HIV dan AIDS Prov. Jateng per Desember 2015.
Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. AIDS Behav. 2011;15:1803–1818.
Letendre, S., Mills, A. M., Tashima, K. T., Thomas, D. A., Min, S. S., Chen, S., ... & McComsey, G. A. (2018). ING116529: a phase 2 study of dolutegravir in combination with abacavir/lamivudine for the treatment of HIV-1 infection. The Journal of Infectious Diseases, 218(5), 744-752.
Lowenhaupt EA, Matson K, Qureishi B, Saitoh A, and Pugatch D (2007) Psychosis in a 12 - year-old HIV-positive girl with an increased serum concentration of efavirenz. Clin Infect Dis 45:e128–e130.
Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, and Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV- 1-infected patients. AIDS 15:71–75
Mekonen T, Belete H, Fekadu W. Depressive symptoms among people with HIV/AIDS in Northwest Ethiopia: comparative study. BMJ Open 2021;11:e048931. doi:10.1136/bmjopen-2021-048931
Mendes, J.C. , Braga , M. das G. , Reis, A.M.M. and Silveira, M.R. 2022. Incidence and factors associated with adverse drug reactions in a cohort of individuals starting dolutegravir or efavirenz . Research, Society and Development. 11, 4 (Mar. 2022), e0811426250.
Morgan, G, Hamilton, C, (2009). Human Immunodeficiency Virus/ Acquired Immunodeficiency Syndrome (HIV/ AIDS). Dalam: Obstetri dan Ginekologi. Jakarta, EGC, 227-235.
Muhtar, M., Julhana, J., Djuwitaningsih, S., Achjar, K. A. H., & Fadlurrahmi, F. (2025). Enhancing HIV / AIDS Prevention in Adolescents?: An Information - Motivation - Behavioral Skills Approach. Journal of Liaquat University of Medical & Health Sciences, 24(04). https://doi.org/10.22442/jlumhs.2025.01272
Muñoz-Moreno JA, Fumaz CR, Ferrer MJ, González-García M, Moltó J, Negredo E, Clotet B. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review. AIDS Rev. 2009 Apr-Jun;11(2):103-9. PMID: 19529750.
Ophinni Y, Adrian, Siste K, et al. Suicidal ideation, psychopathology and associated factors among HIV-infected adults in Indonesia. BMC Psychiatry. 2020;20(1):1-10. doi:10.1186/s12888-020-02666-1
Park TE, Mohamed A, Kalabalik J, et al. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Expert Rev Anti Infect Ther. 2015;13:1195–1212.
Raffi F, Rachlis A, Stellbrink HJ, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013 Jun 29;381(9883):735-43. doi: 10.1016/S0140-6736(13)60530-8. Epub 2013 Apr 29. PMID: 23623440.
Reynes J, Trinh R, Pulido F, et al. LAMIDOL: a randomized, double-blind, noninferiority trial of lamivudine and dolutegravir versus lamivudine and efavirenz in treatment-naive HIV-infected patients. J Acquir Immune Defic Syndr. 2017 May 1;75(1):e17-e24. doi: 10.1097/QAI.0000000000001329. PMID: 28045893.
Saragih (2008). Sindrom Depresif Pada Penderita HIV/AIDS Di RSUP Haji Adam Malik, Medan.https://www.researchgate.net/publication/42324289_Sindrom_Depresif_Pada_Pe nderita_HIVAIDS_Di_RSUP_Haji_Adam_Malik_Medan.
Schlebusch L, Vawda N. HIV-infection as a self-reported risk factor for attempted suicide in South Africa. African J Psychiatry (South Africa). 2010;13:280–3.
Sekar V, Deeks SG. Dolutegravir: a new integrase inhibitor for the treatment of HIV. Expert Opin Investig Drugs. 2014 Jan;23(1):115-22. doi: 10.1517/13543784.2014.849978. Epub 2013 Oct 23. PMID: 24151739.
Sudikno (2011). Pengetahuan HIV/AIDS Pada Remaja Di Indonesia (Analisis data Riskesdas 2010). http://ejournal.litbang.depkes.go.id/index.php/kespro/article/ view/1390.
Sustiva (1998) Sustiva product insert: highlights of prescribing information. Bristol-Myers Squibb, Princeton, NJ.
World Health Organization (2016). HIV/AIDS Fact Sheet. http://www.who.int/mediacentre/factsheets/fs360/en/
Zannou, D. M., Denoeud, L., Lacombe, K., Amoussou-Guenou, M. K., Bashi, J., Akakpo, J., & Azondekon, A. (2018). Dolutegravir-based antiretroviral therapy and neurocognitive function in HIV-infected adults: a randomized trial. HIV medicine, 19(6), 411-419.
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The author who submits the manuscript does so with the understanding that if accepted for publication, the copyright of the article will be submitted to the Bima Nursing Journal Unit Research and Community of Polytechnic of Mataram as the publisher of the journal.
Copyright includes the exclusive right to reproduce and transmit this article in all forms and media, including reprints, photographs, microfilms, and other similar reproductions, as well as its translations. Reproduction of any part of this journal, its storage in the database and its transmissions by any form or media, such as electronic, electrostatic and mechanical copies, photocopies, recordings, magnetic media, etc. shall be permitted only by written permission of the Bima Nursing Journal Unit Research and Community of Polytechnic of Mataram.
The Bima Nursing Journal Unit Research and Community of Polytechnic of Mataram, Editor In Chief and Team Editor strive to ensure that no data or statements are false or misleading, published or published. in the journal.
Â
Â
Every accepted manuscript should be accompanied by the "Copyright Transfer Agreement" prior to the article publication.
Â
Bima Nursing Journal is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
